Therefore, measurement of GH is not useful to monitor treatment of acromegaly with pegvisomant: instead IGF1 is determined as a surrogate biomarker.120,121 In addition, pegvisomant treatment decreases the insulin and glucose concentrations.122. Here, GH1 is linked to acromegaly.